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Key players in the drugs war between
public and private medicine are taking
to the HIV/AIDS trenches as the
antiretroviral drugs battlefield shifts
from accessibility to compliance.
This comes after the government
successfully countered, with costs, the
high-stakes combined legal bid by the
National Convention on Dispensing and
the Affordable Medicines Trust to
declare invalid the new law stripping
doctors of dispensing powers.
Doctors now have to write and pass
the new Pharmaceutical Council exam
before dispensing drugs.
A separate challenge to the single-exit
price and maximum dispensing fee
regulations was in process at the time of
writing while the State roll-out of ARVs
is irretrievably underway in eight of
nine provinces.
These developments coincide with a
dramatic price drop in life-prolonging
HIV/AIDS medicines.
The State view of the private sector
being more interested in their pockets
than the patient again emerged, with at
least one top drug official implying that
cavalier prescribing and poor
monitoring of therapy by some private
doctors was contributing to drug
resistance.
South African Medical Association
(SAMA) Chairperson, Dr Kgosi
Letlape’s rebuttal was that the private
sector was providing and sourcing ARV
drugs long before the State. Clinicians 
had gone to ‘tremendous lengths’ to
make sure patients had ongoing
supplies of difficult-to-get ARV drugs.
Sweeping statements now by officials
who had very little to do with the battle
against HIV and AIDS were ‘short-
sighted and unfortunate’.
‘I’m not saying there aren’t problems
on the ground, but this kind of talk is
destructive,’ he added.
Letlape said the court ruling on
dispensing would have serious
repercussions on the continuing private
treatment of people living with AIDS
and on medication for other chronic
diseases.
Many were cash-paying patients with
no medical scheme cover and relied on
the package deals that doctors offered.
Others simply ran out of medical aid
benefits, creating a compliance
nightmare.
SAMA hoped to meet with the
Ministry of Health ‘very soon’ to ensure
that patients were not adversely
affected.
Letlape called on doctors to record
difficulties of drug access with a view to
finding interim solutions.
`We hope government will take
responsibility for providing access to
drugs for vulnerable communities.
SAMA urges the profession to help find
solutions to ensure continuity of
therapy.’
Another ARV compliance problem is
the cross-border smuggling of cheap
ARV drugs. Unchecked, this activity
would aggravate what Chief Director of
Pharmaceutical Services and Planning,
Humphrey Zokufa, describes as a
crucial phase in the effort to turn the
tide of the pandemic.
He pointed to ‘the lack of a critical
mass’ of adequately trained clinicians
and nurses and the dearth of patient
compliance education as even-larger
existing challenges, ones which the
Treatment Action Campaign (TAC)
echoed loudly in a national review of
the government’s ARV roll-out last
month.
The Zimbabwe Standard newspaper
reported in June that unlicensed drug
merchants were making a mint out of
poorly educated AIDS sufferers in that
country’s debilitated health system.
While a public sector ARV drugs roll-
out began at five Zimbabwean sites in
March this year, the lack of cash and
fuel had by then already boosted ARV
black-market prices and created a fertile
environment for illegal traders.
The newspaper said ARVs were being
smuggled in from South Africa,
Botswana and Namibia. Thousands of
Zimbabweans are seeking better lives in
South Africa, bringing with them the
risk of spreading drug-resistant HIV
strains. At the Zimbabwean dollar price
of Z$315 000 (R356) per month for the
cheapest combination therapy, profits
were ‘there for the taking’, said the
report.
Dr Des Martin, Chairman of the
South African HIV Clinicians Society,
said cross-border smuggling of ARVs
began years ago with drugs coming into
South Africa from Swaziland and
Lesotho, and ‘clearly that’s happening
in Zimbabwe now’. He said drugs that
were not WHO-endorsed and came in
through ‘suspicious routes’ would be of
low quality and impact on security of
supply.
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The danger of magnified toxicities
when body-weight restrictions were not
complied with added to the potential
for disaster. ‘If you put inaccurate
compounds in a pill and call it
anything, you can make a hell of a lot of
money,’ Martin said. Even reputable
generics could be ‘offloaded with some
profit’.
Dr Andrew Jamieson, medical
director of SAA Netcare Travel Clinics,
predicted a similar market for illegal
ARVs in South Africa, ‘as pressure on
supply increases’. He speculated that
impoverished people with no food to
eat could be tempted to on-sell
government-provided ARVs, but
admitted that special packaging could
minimise this practice.
However Martin said that for
profiteers to flourish they would have
to obtain drugs at a ‘totally ridiculous
price – and one must then assume that
the product is worth very little’.
Zokufa said that if doctors prescribed
responsibly, it would free the
government to crack down heavily on
illegal traders and thus protect its
citizens. ‘We may even have to go the
Scorpions route. This is not an issue of
fish and chips; there’s a lot at stake.’
He said all government departments
would have to use all their resources to
protect South Africans.
‘If we don’t handle this right, we will
have failed people – we simply cannot
afford to,’ he said.
Alluding to the court battles over the
new drug legislation, he said it was
‘untenable’ for the medical profession to
be in one camp and the health
department in another. ‘We’re not
fighting the prescripts of the medical
profession. We want the medical
profession to emerge as an important
profession untainted by the commercial
pressures that are there.’
Secretary General of the Zimbabwe
Medical Association, Dr Paul Chimedza,
said ARV drug trafficking was a
common practice, but he was unable to
quantify it. As chief of the Opportunistic
Infections Clinic at Harare Hospital, he
said he personally advised people to
source ARV drugs in South Africa
where they were ‘twice as cheap’.
‘We don’t like to use the word
smuggling – fortunately it’s illegal to
sell or distribute drugs without a
licence, and as an association and a
profession we cannot condone it. ‘He
said the only way to eliminate the black
market was to make drugs available.
HIV prevalence in Zimbabwe is
estimated at 24.6%.
Chimedza said he knew of 150 people
on ARVs at one site in Bulawayo and
another 80 on ARVs at two sites in
Harare (three of five public sector sites),
while in the private sector there were no
statistics currently available. People
who could not afford triple therapy got
it for free, and those who could do so
paid half price (Z$157 500 or R178).
A ‘big step’ this year had been the
setting up of two companies
manufacturing generic drugs that came
on stream about 3 months ago. Things
were ‘looking up’ with inflation
dropping from 600% last year to an IMF
prediction of 175% by the end of this
year.
‘At our perinatal hospital we’re able
to supply about 70% of the drugs
required, which is a huge improvement
on last year when nothing was
available,’ Chimedza added.
In South Africa 10 000 people in the
private sector and 5 500 in the public
sector are estimated (the latter by the
TAC) to be on triple therapy. At the time
of going to press the TAC was bringing
a court application using the Promotion
of Access to Information Act to force the
national Health Minister, Dr Manto
Tshabalala-Msimang, to reveal time
lines and targets in the government’s
ARV roll-out. She had until 12 July to
respond.
Professor Robin Wood, head of the
Desmond Tutu HIV Centre at the
University of Cape Town, said he was
not aware of any ARV black market
locally. ‘I think the big fear everyone has
is that cheap drugs in the developing
world will get back into the big market
in the West,’ he said.
Backing Zokufa’s assertion that
private doctors should apply their
minds carefully and ‘not just prescribe
ARVs willy-nilly’, Wood said he saw no
money going into adherence counselling
in the private sector.
‘The State
programme is





get a script and off
you go. Ask
yourself which one




was severe prejudice towards poor
people when it came to compliance.
However, Cape Town research of
township ARV trials showed
compliance of 90% over 48 weeks, 20%
better than that reported in developed
countries with people on similar
regimens.
‘We’ve published some predictors as
to who does and who does not take
tablets, but where you live and how
much money you make does not make
you a better tablet-taker.’
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Although he was not aware of any
local black-market ARV drug
smuggling, he agreed that there was
potential for money to be made by
unscrupulous private practitioners.
Wood said the cheapest generics on the
market (not licensed but on Section 21)
came from India and cost the patient
about R20 per month. 
Zokufa said that unless compliance
and monitoring were handled properly,
all the efforts the government was
making to get drugs on tender at very
reduced prices would be ‘reduced to
naught’.
‘We’d then have to look at second-
and third-generation ARVs at much
higher prices, and we’d be back to
square one, chasing our tails.’
The pharmaceutical industry needed a
market for their second- and third-
generation ARVs.
‘We must do the first-stage roll-out
very well – as it is, we’ve moved faster
than we’d have liked to.’
While the quotation system was being
used as an interim measure to purchase
ARV drugs, tenders would ‘definitely’ be
finalised by the beginning of September.
Drug planning centred on supplying
450 000 people with ARVs.
‘Obviously not everyone will show
up on day one – we’ll probably hit that
figure in 6 - 8 months’ time,’ Zokufa
said.
Chris Bateman
Public health care workers have a year
longer than their recently shaken
private counterparts to comply with the
tightened-up drug dispensing
regulations and will be equally bound
by them from 1 July next year.
In spite of the extra time, provincial
human resource and pharmacy
departments are scrambling to make
sense of the plethora of interlocking
laws aimed at improving service
delivery and creating greater
accessibility to health care.
Contrary to the fiercely contested but
ultimately accepted inception of the
dispensing section of the Medicines Act
by the private sector, some in the public
sector are viewing the changes as an
opportunity to review best practice.
Says Margaret van Zeil, head of
pharmacy practice and legislation in the
Western Cape provincial administration,
‘for example, if we think we may need
20 – 30 nurses licensed to dispense at a
hospital, that assumes they need to
dispense after hours for patients
discharged on a Friday night or
Saturday afternoon. So instead we
question why we’re dispensing
medicines on a Friday night or Saturday
morning and look at doing things
differently.’
Her boss, Mrs Vonita Thompson,
Director of Professional Support
Services for the Western Cape, added,
‘basically we’re almost re-engineering
the services, talking with every regional
director and detailing and modelling
every region’.
Van Zeil said the support being
received from top provincial
management was ‘heartening’.
‘There appears to be commitment and
understanding of the legislation and
compliance with it. It’s a fantastic
opportunity and a good weapon to
enforce compliance and good practice,’
she added.
Provincial health departments, even
those with efficient spending, capable
management and supportive
infrastructure, simply cannot deliver
without nurses prescribing and
dispensing medicines. Nurses offer the
bulk of care at primary and district level
and can currently prescribe lower
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